{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Abbott Laboratories
Abbott Laboratories Hits New 52-Week Low at USD 104.11
Abbott Laboratories has reached a new 52-week low, trading at USD 104.11, reflecting a decline in stock performance over the past year. Despite this, the company maintains a strong financial position with low debt levels and consistent operational resilience, reporting positive results for three consecutive quarters.
Abbott Laboratories Stock Hits Day Low of $105.40 Amid Price Pressure
Abbott Laboratories' stock fell significantly today, contrasting with the broader market's decline. Over the past week and month, the stock has shown notable decreases, and it has faced challenges over the past year. Despite this, the company maintains strong financial health, evidenced by positive cash flow and a low Debt to EBITDA ratio.
Abbott Laboratories Faces Weak Start with Gap Down Amid Market Concerns
Abbott Laboratories has opened with a significant loss, continuing a downward trend over the past month. Technical indicators suggest a bearish sentiment, with the stock's price-to-earnings ratio at 32.00 and a market capitalization of around USD 214.68 billion, reflecting its large-cap status.
Abbott Laboratories Stock Hits Day Low of $107.14 Amid Price Pressure
Abbott Laboratories' stock declined significantly today, contrasting with the S&P 500's modest decrease. Over the past week and month, Abbott has also seen declines, with a notable annual drop. Despite these fluctuations, the company maintains a strong financial position, evidenced by a low Debt to EBITDA ratio and consistent operating profit growth.
Is Abbott Laboratories overvalued or undervalued?
As of November 21, 2025, Abbott Laboratories is rated as attractive, fairly valued with a P/E ratio of 19, and has outperformed the S&P 500 year-to-date, despite a recent stock price decline and underperformance over the past three to five years.
Is Abbott Laboratories overvalued or undervalued?
As of November 21, 2025, Abbott Laboratories is rated as attractive, with a P/E ratio of 19, an EV to EBITDA of 25.84, and a PEG ratio of 0.14, indicating fair valuation and strong growth potential compared to peers like Thermo Fisher and Stryker, despite a one-year return of 9.25% trailing the S&P 500's 11.00%, while outperforming it year-to-date with a return of 13.26% versus 12.26%.
Abbott Laboratories Experiences Revision in Stock Evaluation Amid Market Dynamics
Abbott Laboratories has recently revised its evaluation amid changing market conditions. The stock is priced at $131.38, reflecting a year of notable highs and lows. Technical indicators present mixed signals, while Abbott's year-to-date performance has outpaced the S&P 500, though longer-term returns remain less competitive.
Is Abbott Laboratories technically bullish or bearish?
As of October 10, 2025, Abbott Laboratories shows a mildly bullish trend, supported by a bullish monthly MACD and KST, despite a mildly bearish weekly MACD and mixed performance indicators, having outperformed the S&P 500 recently but lagged over longer periods.
Is Abbott Laboratories technically bullish or bearish?
As of September 12, 2025, Abbott Laboratories is in a bullish trend with strong indicators, outperforming the S&P 500 recently but lagging in long-term returns.
Is Abbott Laboratories overvalued or undervalued?
As of July 17, 2025, Abbott Laboratories is fairly valued with a P/E ratio of 19 and strong growth potential, outperforming peers like Thermo Fisher but lagging in long-term returns compared to the S&P 500.
Abbott Laboratories Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators
Abbott Laboratories has recently revised its evaluation amid changing market conditions. The stock is priced at $131.33, with a year-to-date return of 16.11%, outperforming the S&P 500. However, its longer-term performance over three and five years lags behind the broader market, indicating mixed results.
Is Abbott Laboratories technically bullish or bearish?
As of June 17, 2025, Abbott Laboratories has a mildly bullish trend, supported by bullish monthly indicators and daily moving averages, though tempered by mixed signals from weekly indicators.
Is Abbott Laboratories overvalued or undervalued?
As of June 18, 2025, Abbott Laboratories is considered a very attractive investment due to its undervalued P/E ratio of 19, impressive PEG ratio of 0.14, strong ROE of 27.70%, and favorable comparisons to peers, along with a year-to-date return of 17.81% that significantly outperforms the S&P 500.
Who are in the management team of Abbott Laboratories?
As of March 2022, Abbott Laboratories' management team includes Executive Chairman Miles White, CEO Robert Ford, Lead Independent Director William Osborn, and Independent Directors Robert Alpern, Roxanne Austin, Sally Blount, and Michelle Kumbier. They are responsible for guiding the company's strategic direction and operations.
What does Abbott Laboratories do?
Abbott Laboratories is a large-cap company that develops and sells a wide range of healthcare products in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $10.36 billion and a net profit of $1.3 billion, with a market cap of approximately $258.56 billion.
How big is Abbott Laboratories?
As of Jun 18, Abbott Laboratories has a market capitalization of $258.56 billion, with recent net sales of $42.34 billion and a net profit of $13.43 billion.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
